Mammography computer-aided detection firm R2 Technology’s ImageChecker CAD unit has received approval from the Japanese Ministry of Health and Welfare for use in breast cancer screening in Japan. The unit will be distributed by R2’s partner,
Mammography computer-aided detection firm R2 Technologys ImageChecker CAD unit has received approval from the Japanese Ministry of Health and Welfare for use in breast cancer screening in Japan. The unit will be distributed by R2s partner, Marubeni America, with which R2 signed an agreement last spring (SCAN 6/23/99).
The MHWs decision came as more good news for the Los Altos, CA, company, which is seeing its efforts to establish industry alliances pay off. In 1998, R2 signed an exclusive OEM supply deal with GE Medical Systems of Milwaukee. GE agreed to bundle ImageChecker with the full-field digital mammography system it had under development (SCAN 4/29/98). With the Food and Drug Administrations Jan. 31 approval of GEs Senographe (see story, page 5), R2 comes closer to bringing a digital version of ImageChecker to market.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.